Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
(D09314)
[3] Ocrelizumab,
Ofatumumab,
Rituximab
[3] Rituximab ,
Ocrelizumab ,
Ofatumumab (D09314) 💬
[1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
2Combination Product: ofatumumab with AI
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
3Combination Product: ofatumumab with PRF
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
4Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(D09314)
[12] Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide
[13] Cladribine ,
Alemtuzumab ,
Rituximab ,
Dimethyl fumarate ,
Fingolimod hydrochloride ,
Glatiramer acetate ,
Ocrelizumab ,
Natalizumab ,
Ofatumumab (D09314),
Fingolimod ,
Teriflunomide ,
Ponesimod ,
Fingolimod lauryl sulfate 💬
[26] DHODH,
HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬
[58] Allograft rejection, Antigen processing and presentation, Arrhythmogenic right ventricular cardiomyopathy, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Chemical carcinogenesis - reactive oxygen species, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Efferocytosis, Endocytosis, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Graft-versus-host disease, Hematopoietic cell lineage, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Integrin signaling, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Phagocytosis, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Rheumatoid arthritis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Ubiquitin mediated proteolysis, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬[1] 13 💬
5Ofatumumab
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[6] 11, 13, 35, 46, 222, 223 💬
6Ofatumumab 100
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
7Ofatumumab 300
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
8Ofatumumab 30mg
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
9Ofatumumab 3mg
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
10Ofatumumab 60mg
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
11Ofatumumab 700
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
12Ofatumumab approved dose
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
13Ofatumumab new dose
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
14Ofatumumab subcutaneous injection
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[2] 13, 35 💬
15Other: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
(D09314)
[8] Alemtuzumab,
Cladribine,
Hyaluronidase,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Rituximab,
Ublituximab
[10] Cladribine ,
Alemtuzumab ,
Rituximab ,
Hyaluronidase ,
Hyaluronidase ,
Ocrelizumab ,
Hyaluronidase ,
Natalizumab ,
Ofatumumab (D09314),
Ublituximab 💬
[3] ITGA4,
MS4A1,
RRM1 💬
[21] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecule (CAM) interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Focal adhesion, Glutathione metabolism, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Integrin signaling, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
16Other: Ofatumumab
(D09314)
[1] Ofatumumab[1] Ofatumumab (D09314) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬